Prostate Cancer Aggressiveness Test Able to Determine Metastasis Risk in African Americans

NEW YORK (GenomeWeb) – At a medical meeting last week, researchers presented data from a study that included a large number of biopsy samples from African-American men and concluded that Myriad Genetics’ prostate cancer aggressiveness test Prolaris can accurately determine the risk of metastases in this group with a high disease burden.

In the study presented at the American Urological Association’s annual meeting, researchers used Prolaris to retrospectively test samples from nearly 700 men — 38 percent were African American — who were diagnosed with localized prostate cancer at the Ochsner Clinic in New Orleans and treated between 2006 and 2011. Investigators led by Stephen Bardot, a urologist at the Ochsner Clinic Foundation in Louisiana, and Steven Stone, VP of cancer genomics at Myriad, found that the Prolaris score was a strong predictor of which patients would see their cancer metastasize over 10 years and whether they’d experience biochemical recurrence.

Prolaris analyzes expression of 46 genes that can drive tumor growth, and provides a score that translates to high, intermediate, and low risk of disease mortality. Myriad has evaluated Prolaris in a dozen published studies in order to show that men deemed low risk by the test can be candidates

Be the first to comment

Leave a Reply

Your email address will not be published.